Esperion Therapeutics, Inc. ESPR
We take great care to ensure that the data presented and summarized in this overview for Esperion Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ESPR
View all-
Black Rock Inc. New York, NY14MShares$17.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.5MShares$14 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT10.9MShares$13.3 Million0.09% of portfolio
-
Bellevue Group Ag Kuesnacht, V89.69MShares$11.8 Million0.32% of portfolio
-
Two Seas Capital LP Rye, NY6.93MShares$8.46 Million0.36% of portfolio
-
Morgan Stanley New York, NY6.59MShares$8.04 Million0.0% of portfolio
-
State Street Corp Boston, MA4.55MShares$5.55 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA4.45MShares$5.42 Million0.0% of portfolio
-
Meditor Group LTD3.79MShares$4.63 Million12.99% of portfolio
-
Marshall Wace, LLP London, X03.63MShares$4.43 Million0.01% of portfolio
Latest Institutional Activity in ESPR
Top Purchases
Top Sells
About ESPR
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Insider Transactions at ESPR
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 17
2025
|
Benjamin Halladay Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
11
-0.0%
|
$11
$1.12 P/Share
|
|
Jul 17
2025
|
Benjamin Looker General Counsel |
SELL
Open market or private sale
|
Direct |
1,304
-0.33%
|
$1,304
$1.13 P/Share
|
|
Jun 17
2025
|
Benjamin Looker General Counsel |
SELL
Open market or private sale
|
Direct |
6,422
-1.58%
|
$6,422
$1.15 P/Share
|
|
Jun 17
2025
|
Benjamin Halladay Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
7,229
-1.5%
|
$7,229
$1.15 P/Share
|
|
Jun 17
2025
|
Sheldon L. Koenig President and CEO |
SELL
Open market or private sale
|
Direct |
30,474
-1.94%
|
$30,474
$1.11 P/Share
|
|
May 29
2025
|
Seth H. Z. Fischer Director |
BUY
Grant, award, or other acquisition
|
Direct |
33,000
+35.05%
|
-
|
|
May 29
2025
|
J Martin Carroll Director |
BUY
Grant, award, or other acquisition
|
Direct |
33,000
+25.26%
|
-
|
|
May 29
2025
|
Jay Shepard Director |
BUY
Grant, award, or other acquisition
|
Direct |
33,000
+28.06%
|
-
|
|
May 29
2025
|
Stephen Rocamboli Director |
BUY
Grant, award, or other acquisition
|
Direct |
33,000
+32.27%
|
-
|
|
May 29
2025
|
Robert E. Hoffman Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,280
+50.0%
|
-
|
|
Apr 17
2025
|
Benjamin Halladay Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
8
-0.0%
|
$0
$0.96 P/Share
|
|
Apr 17
2025
|
Eric Warren Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
108
-0.03%
|
$0
$0.98 P/Share
|
|
Mar 18
2025
|
Sheldon L. Koenig President and CEO |
SELL
Open market or private sale
|
Direct |
13,047
-0.82%
|
$13,047
$1.5 P/Share
|
|
Mar 18
2025
|
Eric Warren Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,433
-0.65%
|
$2,433
$1.49 P/Share
|
|
Mar 18
2025
|
Benjamin Halladay Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,535
-0.73%
|
$3,535
$1.48 P/Share
|
|
Mar 14
2025
|
Benjamin Looker General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
224,000
+35.46%
|
-
|
|
Mar 14
2025
|
Eric Warren Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
213,000
+36.36%
|
-
|
|
Mar 14
2025
|
Benjamin Halladay Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
238,000
+32.91%
|
-
|
|
Mar 14
2025
|
Sheldon L. Koenig President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
840,000
+34.64%
|
-
|
|
Feb 19
2025
|
Benjamin Halladay Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
11
-0.0%
|
$11
$1.86 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 1.65M shares |
|---|
| Open market or private sale | 101K shares |
|---|